Diatheva’s pipeline antibody-based therapies is designated to address significant unmet medical needs and by its productive technology suite capable of selecting, manufacturing in GMP compliance and characterizing innovative next generation recombinant antibody therapeutics.
Published article: Process development of a human recombinant diabody expressed in E.coli: engagment of CD99 induced apoptosis for target therapy in Ewing’s sarcoma.
